Japan’s FY2026 Drug Price Revision Took Effect in April 2026 with Tighter Premium Rules

Japan revises National Health Insurance (NHI) drug prices on a regular cycle, with major reforms of the pricing rules accompanying the biennial medical fee revision. For FY2026, the Central Social Insurance Medical Council (Chuikyo) approved the outline of the drug pricing reform on 26 December 2025 and issued its recommendation on the FY2026 medical fee revision on 13 February 2026. The revised prices and rules took effect in April 2026.

According to an analysis by GlobalData, the revision produced an average reduction of 4.02% on a spending basis across roughly 15,800 products. This was a smaller average rate of reduction than in the previous biennial round, although another analysis notes that the scope of affected products widened. Trade press reported that Chuikyo rejected several key industry requests when it backed the outline.

The price maintenance premium, which protects the prices of innovative medicines during their patent period, was renamed the Patent-Period Price Maintenance Program for Innovative Drugs, keeping the abbreviation PMP. Analyses of the reform report that its eligibility was tightened through stricter criteria and the removal of certain qualifying conditions, and that a price-floor rule for drugs with a new mechanism of action was dropped. Trade press reported individual cases in which products returned price reductions on leaving the PMP, including a 36% cut for Forxiga.

Market expansion repricing was also revised. Chuikyo abolished the so-called spillover rule, under which drugs similar to a repriced product could themselves be repriced, while adding new follow-up rules. The rule for very high-selling products was renamed a special price adjustment for sustainable products, and one analysis reports that price cuts for high-revenue products can now reach up to 66.7%. Commentators also identified the expansion of the G1 repricing framework, which applies to long-listed originator products after generic entry, as one of the most consequential changes; the detailed G1 rules should be checked against MHLW documents.

On cost-effectiveness evaluation, trade press headlines were not consistent, with one reporting that expansion was put on hold pending six months of technical discussions and another reporting approval of new handling with third-party verification. The final position could not be confirmed from the sources reviewed for this brief. Japan also set new pricing rules for conditionally approved regenerative medicines.

Japan has conducted off-year price revisions in the years between the biennial revisions. The Government’s June 2026 basic policy draft (honebuto) confirmed that an FY2027 off-year revision will take place. Chuikyo’s drug pricing subcommittee began discussions on 8 July 2026, when no member objected to holding the revision.

Positions diverged at the subcommittee meeting on 7 October 2026. Healthcare providers argued that savings from price cuts should be returned to medical fees, payers considered a broader range of target products, and the pharmaceutical industry asked for NHI price increases to reflect inflation and a freeze on cuts for patent-protected medicines. On 14 October 2026, Prime Minister Takaichi said the Government would consider the necessary measures for the FY2027 revision from the perspectives of pharmaceutical innovation, stable supply and relief of the public’s financial burden. The scope of the FY2027 revision had not been decided at the time of checking and was expected to be settled in December 2026.

Commentators read the FY2026 package as continuing to push prices downwards over the product lifecycle, while keeping innovation incentives in principle. For manufacturers of innovative medicines, the tighter PMP criteria mean that eligibility can no longer be assumed, and launch planning in Japan should include an early assessment of whether a product is likely to qualify. For established products, the widened G1 rules and revised repricing for high-selling medicines increase the risk of significant price reductions.

Pricing and market access teams should model both the April 2026 rules and the range of possible FY2027 outcomes, and should follow Chuikyo materials directly, since many of the details are set out only in Japanese-language MHLW documents.

For medical writers and evidence teams, the reform reinforces the importance of documenting a product’s innovativeness at the time of listing, since premium eligibility and later repricing decisions draw on how the product is characterised. Clear presentation of comparative clinical data, novelty and usefulness in Japanese submissions can support a product’s position under the revised rules, although final decisions rest with the MHLW and Chuikyo.